1Lynch TJ,Bell DW,Sordellar R,et al.Activating mutation in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to Gefitinib[J].N Engl J Med,2004,350(21):2129.
2Paze JG,Jane PA,Lee JC,et al.EGFR mutations in lung cancer:Correlation with clinical response to Gefitinib therapy[J].Science,2004,304(5676):1497.
3Giannarelli D,Bria E,Milella M,et at.First-line gefitinib(G)for advanced non-small cell lung cancer(NSCLC)patients(pts)harbouring sensitizing epidermal growth factor receptor mutations(EGFR M +):Meta-analysis of randomized trials(RCT)exploring the magnitude of benefits over chemotherapy(CT)[J].J Clin Oncol,2010,28(Suppl):Abstr e18076.
4Wu YL,Zhong WZ,Li LY,et al.Epidermal growth factor receptor mutations and their correlation with Gefitinib therapy in patients with non-small cell lung cancer:A meta-analysis based on updated individual patient data from six medical centers in China's Mainland[J].J Thorac Oncol,2007,2(5):43O.
5Bang Y,Kwak EL,Shaw A,et at.Clinical activity of the oral ALK inhibitor,PF-O2341066,in ALK-positive patients with non-small cell lung cancer(NSCLC)[J].J Clin Oncol,2010,28(18S):3.
6Soda M,Choi YL,Enomoto M,et at.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J].Nature,2007,448(7153):561.
7Soda M,Takada S,Takeuchi K,et at.A mouse model for EML4-ALK-positive lung cancer[J].Proe Nail AcadSci USA,2008,105(50):19893.
8Inamura K,Takeuehi K,Tngashi Y,et al.EMIA-ALK fusion is linked to histological characteristics in a subset of lung cancers[J].J Thorac Oncol,2008,3(1):13.
9Inamura K,Takeuchi K,Togashi Y,et al.EMIA-ALK lung cancers are characterized by rare other mutations,a TTF-1 cell lineage,an acinar histology,and young onset[J].Mod Pathol,2009,22(4):508.
10Koivunen JP,Mermel C,Zejnullahu K,et at.EMIAALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer[J].Clin Cancer Res,2008,14(13):4275.
2Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007,448:561-566.
3Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of EMIA-ALK non-small cell lung cancer. Eur J Cancer, 2010,46 : 1773-1780.
4Yoshida A, Tsuta K, Watanabe S, et al. Frequent ALK rearrangement and TTF-I/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer, 2011,72:309-315.
5Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science, 1994,263 : 1281-1284.
6Hernandez L, Pinyol M, Hernandez S, et al. TRK-fused gene (TFG) is a newpartner of ALK in anaplastic large cell lymphoma producing twostructurally different TFG-ALK translocations. Blood, 1999,94:3265-3268.
7Wang DW, Leung EL, Wong SK, et al. A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer, 2011,117 : 2709- 2718.
8Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gent rearrangement : a retrospective analysis. Lancet Oncol, 2011,12 : 1004-1012.
9Kimura H, Nakajima T, Takeuchi K, et al. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. Lung Cancer, 2012,75:66-72.
10Normant E, Paez G, West KA, et al. The Hsp90 inhibitor IPI- 504 rapidly lowers EMIA-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene, 2011,30:2581-2586.
